Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by Analysts at Robert W. Baird

Robert W. Baird initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note released on Friday morning, Marketbeat.com reports. The firm issued an outperform rating and a $58.00 price target on the stock.

Several other brokerages also recently weighed in on DNTH. Lifesci Capital upgraded shares of Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Raymond James lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an outperform rating in a research report on Thursday, April 18th. Wedbush raised their target price on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an outperform rating in a research note on Friday, May 10th. HC Wainwright started coverage on shares of Dianthus Therapeutics in a research note on Thursday, May 16th. They set a buy rating and a $40.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an overweight rating on the stock. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of Buy and a consensus target price of $45.00.

Dianthus Therapeutics Stock Up 3.1 %

Shares of NASDAQ:DNTH opened at $28.97 on Friday. The company has a market cap of $850.27 million, a PE ratio of -4.97 and a beta of 1.89. The company’s 50-day moving average price is $25.27 and its 200 day moving average price is $23.93. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The company had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. As a group, equities analysts anticipate that Dianthus Therapeutics will post -2.18 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the business. Octagon Capital Advisors LP grew its stake in shares of Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares during the last quarter. Vestal Point Capital LP acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $1,404,000. Citigroup Inc. acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $53,000. Hussman Strategic Advisors Inc. purchased a new position in shares of Dianthus Therapeutics in the first quarter worth approximately $630,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.